IST:SELEC's ROE % is ranked worse than 62.61% of 115
companies
in the Medical Distribution industry
Industry Median: 7.1
vs IST:SELEC: 4.06
Selcuk Ecza Deposu Ticaret venayi AS (IST:SELEC) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Selcuk Ecza Deposu Ticaret venayi AS ROE % Related Terms
Selcuk Ecza Deposu Ticaret venayi AS ROE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Selcuk Ecza Deposu Ticaret venayi AS's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Selcuk Ecza Deposu Ticaret venayi AS ROE % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Selcuk Ecza Deposu Ticaret venayi AS's ROE % distribution charts can be found below:
* The bar in red indicates where Selcuk Ecza Deposu Ticaret venayi AS's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Selcuk Ecza Deposu Ticaret venayi AS (IST:SELEC) has a ROE % of 19.11% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Selcuk Ecza Deposu Ticaret venayi AS and its competitors. This is 35% above median its historical median of 14.16. According to the industry distribution chart, Selcuk Ecza Deposu Ticaret venayi AS ranks #72 out of 115 companies in the Medical Distribution industry, placing it in the top 62.6%.
Is Selcuk Ecza Deposu Ticaret venayi AS's ROE % too high?
Selcuk Ecza Deposu Ticaret venayi AS's current ROE % of 19.11% is 35% above median its 10-year median of 14.16. The Medical Distribution industry median ROE % is 7.10. Selcuk Ecza Deposu Ticaret venayi AS's value of 19.11% is 169.2% above this industry median. Based on the distribution chart, Selcuk Ecza Deposu Ticaret venayi AS ranks #72 out of 115 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Selcuk Ecza Deposu Ticaret venayi AS has a GF Score™ of 79/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Selcuk Ecza Deposu Ticaret venayi AS's ROE % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Selcuk Ecza Deposu Ticaret venayi AS ranks #72 out of 115 companies for ROE %. This places Selcuk Ecza Deposu Ticaret venayi AS in the lower half of its industry. The industry median ROE % is 7.10. Selcuk Ecza Deposu Ticaret venayi AS's value of 19.11% is 169.2% above this benchmark. While the company's 10-year median is 14.16 vs. the industry median of 7.10, Selcuk Ecza Deposu Ticaret venayi AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Distribution company?
The median ROE % among Medical Distribution companies is 7.10, based on 115 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Selcuk Ecza Deposu Ticaret venayi AS's current ROE % of 19.11% is 169.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Selcuk Ecza Deposu Ticaret venayi AS and its competitors. For the Medical Distribution industry, the median ROE % is 7.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Selcuk Ecza Deposu Ticaret venayi AS's current ROE % is 19.11%, which is 35% above median its own 10-year median of 14.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Selcuk Ecza Deposu Ticaret venayi AS stock overvalued right now?
Based on GuruFocus' analysis, Selcuk Ecza Deposu Ticaret venayi AS (IST:SELEC) is currently considered Significantly Overvalued. The stock's GF Value™ is ₺86.35, compared to a current price of ₺198.30 — trading 129.6% above its estimated fair value. The current ROE % is 19.11%, which is 35% above median its 10-year median of 14.16 and 169.2% above the Medical Distribution industry median of 7.10. Selcuk Ecza Deposu Ticaret venayi AS's overall GF Score™ is 79/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Selcuk Ecza Deposu Ticaret venayi AS (IST:SELEC), the current ROE % is 19.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Selcuk Ecza Deposu Ticaret venayi AS (IST:SELEC) Overvalued in 2026?
Based on GuruFocus' analysis, Selcuk Ecza Deposu Ticaret venayi AS stock appears to be overvalued.
The current stock price of ₺198.30 is trading 129.6% above its estimated GF Value™ of ₺86.35.
GuruFocus considers Selcuk Ecza Deposu Ticaret venayi AS to be Significantly Overvalued.
Key valuation signals for IST:SELEC:
ROE %: 19.11% (35% above median its 10-year median of 14.16)
GF Value™: ₺86.35 vs. price of ₺198.30 (129.6% above fair value)
Industry Position: 169.2% above the Medical Distribution median (#72 of 115)
No single metric tells the full story. See the IST:SELEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Selcuk Ecza Deposu Ticaret venayi AS Business Description
Selcuk Ecza Deposu Ticaret ve Sanayi AS and its subsidiaries are in the business of export and import of drugs and patent medicines, medical supplies with pharmacy depot operations and also organize distribution channels between drug manufacturers, hospitals, and pharmacies. The company also distributes cosmetics, personal care, infant food, vitamins, medical and similar products.
79GF Score
Get the complete analysis for IST:SELEC
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:SELEC has been successfully added to your 
